BC0335

BC0335 is an orally bioavailable small molecule antiviral agent developed by Shandong Danhong Pharmaceutical, a subsidiary of Shandong Buchang Pharmaceuticals, for the treatment of respiratory syncytial virus (RSV) infection. It functions as a fusion inhibitor, specifically targeting the RSV fusion (F) protein. By binding to the F protein, BC0335 prevents the conformational changes necessary for the viral envelope to fuse with the host cell membrane, thereby blocking viral entry and subsequent replication. The drug is primarily intended to address the significant unmet medical need for effective RSV treatments in both pediatric and elderly populations. It has been evaluated in early-stage clinical trials to determine its safety, tolerability, and pharmacokinetic profile.